GSK Reports Strong 2025 Financial Growth, 5 Major FDA Approvals, and Increased Dividends
GSK sits 68% above its 52-week low of $32.38.
Summary
GSK plc reported strong 2025 financial results with significant profit and EPS growth, driven by Specialty Medicines and five major FDA approvals. The company also announced increased dividends and a substantial share buyback program, alongside a CEO transition and strategic focus on R&D and technology.
Key Events · Earnings and Guidance · GSK
-
Strong 2025 Financial Performance
GSK reported a 7% CER increase in turnover, over 100% CER growth in operating profit, and over 100% CER growth in total earnings per share for 2025, primarily driven by its Specialty Medicines segment.
-
Five Major FDA Product Approvals
The company secured five significant FDA approvals in 2025 for Exdensur (severe asthma), Blenrep (multiple myeloma), Nucala (COPD), Blujepa (uUTI/gonorrhoea), and Penmenvy (meningitis vaccine).
-
Increased Shareholder Returns
GSK declared a 66p dividend per share for 2025, up from 61p in 2024, and projected 70p for 2026. The company also executed £1.377 billion of its £2 billion share buyback program by year-end 2025.
-
Strategic Pipeline Advancement and Acquisitions
The R&D pipeline saw 17 assets in Phase III and 7 pivotal trial starts, with strategic acquisitions like IDRx and Empirico strengthening key therapeutic areas. However, some R&D programs were discontinued due to efficacy criteria.
Analysis · GSK · Life Sciences
GSK's 2025 annual report showcases a robust year, with significant growth in operating profit and earnings per share, reflecting strong performance in its Specialty Medicines portfolio. The company's R&D efforts yielded five major FDA approvals and advanced numerous pipeline assets, signaling future growth potential. A notable increase in dividends for 2025 and a positive outlook for 2026, coupled with a substantial share buyback program, underscore management's confidence and commitment to shareholder returns. The transition to a new CEO, Luke Miels, with a clear strategic focus on R&D acceleration and technology adoption, positions GSK for continued momentum.
At the time of this filing, GSK was trading at $54.41 on NYSE in the Life Sciences sector, with a market capitalization of approximately $111.1B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.